A live webcast of
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.MacroGenics.com.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about
future expectations, plans and prospects for the Company, including
statements about the Company's strategy, future operations,
clinical development of the Company's therapeutic candidates,
milestone or opt-in payments from the Company's collaborators, the
Company's anticipated milestones and future expectations and plans
and prospects for the Company and other statements containing the
words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials,
availability and timing of data from ongoing clinical trials,
expectations for regulatory approvals, other matters that could
affect the availability or commercial potential of the Company's
product candidates and other risk factors described in the
Company's filings with the
Jim Karrels, Vice President, CFO MacroGenics, Inc.1-301-251-5172, email@example.com Karen Sharma, Vice President MacDougall Biomedical Communications1-781-235-3060, firstname.lastname@example.org
News Provided by Acquire Media